Aventis Pharma today said it has completed the sale of its 49 per cent stake in Chiron Behring Vaccines Private Ltd (CBVPL) to its joint venture partner Novartis Vaccines & Diagnostics Inc for Rs 100 crore.
The company, which completed stake sale on December 23, received sale consideration of Rs 1,007.5 million ($22.399 million), Aventis Pharma said in a filing to the Bombay Stock Exchange (BSE).
All legal proceedings filed in connection with the disputes between the company and Novartis Vaccines & Diagnostics Inc/ CBVPL have been unconditionally withdrawn by all parties, it added.
The two partners had been fighting a legal battle over marketing of Aventis' anti-rabies vaccine Verorab.
The company has entered into a new service agreement to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from December 23,2010, it added.
Aventis Pharma's two nominees on the board of CBVPL have also resigned, following the stake sale.
Shares of Aventis Pharma today closed at Rs 1,897 on the BSE, up 1.88 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app